Fig. 5From: Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for \(^{177}\)Lu-DOTATATE therapyAbsorbed doses (Gy) estimated for 13 patients of the patient cohort, for three bone marrow VOI types (trabecular part of vertebrae from L2 to L4, from L1 to L5 and from T9 to L5) and, for humerus as a control. For patient 13, the arms are not in the field of view of any of the imagesBack to article page